XMD16-5 is an inhibitor of tyrosine kinase non-receptor 2 (TNK2; IC50 = 0.38 µM), which contains mutations in certain cancer cells. It also decreases viability of Ba/F3 cells expressing the oncogenic TNK2 D163E and R806Q mutant proteins (IC50s = 16 and 77 nM, respectively) without affecting viability of parental cell lines up to a concentration of approximately 1 µM.
XMD16-5 is an inhibitor of tyrosine kinase non-receptor 2 (TNK2; IC50 = 0.38 µM), which contains mutations in certain cancer cells. It also decreases viability of Ba/F3 cells expressing the oncogenic TNK2 D163E and R806Q mutant proteins (IC50s = 16 and 77 nM, respectively) without affecting viability of parental cell lines up to a concentration of approximately 1 µM.
Shipping & Handling
Shipped In
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.